Semaglutide in Nonalcoholic Fatty Liver Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT05813249
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Sponsor
- Zagazig University
- Registry
-
NCT05813249
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05813249. Non-randomized; no masking; primary purpose treatment. Start 2023-02-15 (actual); primary completion 2024-02-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide in Nonalcoholic Fatty Liver Disease
- Condition
- Non-alcoholic Fatty Liver Disease
- Intervention (Drug)
- Rybelsus Oral Product
- Intervention (Drug)
- Ozempic Injectable Product
- Intervention (Drug)
- Tocopherol and/or Actos
- Lead sponsor
- Zagazig University
Record details
- Record id
cardio:ct-nct05813249- Content hash
2e78caf122c05b9b01de56b7369b720bad0dad8ba209687572c6aa8bf00d4f00